



BHVN
LISTED
NYSE

EURO-Ataxia

Anne Neumann, RN BSN
Patient Advocacy and Engagement Lead

20 May, 2023

HIGH VALUE PLATFORMS

Pursuing novel paths of **science** to transform the treatment of neurological and neuropsychiatric diseases

INNOVATIVE PORTFOLIO

A broad therapeutic **portfolio** addressing patient needs with intention.

PROVEN BUSINESS FORMULA

Formula for continued **growth** built upon past success of experienced team and a resilient focus on creating value for patients and shareholders

BIOHAVEN TODAY



Registry data is important for industry to better understand the patient community

- Registries like EURO-SCA are important to industry partners like Biohaven to get a better understanding of the patient demographics and disease natural history.
- Partnership with patient advocacy groups to understand the patient community in each country and to advocate for patients to enroll in SCA registries.

Troriluzole in Spinocerebellar Ataxia (SCA)

- **No current therapy for SCA**

Biohaven's development program has been underway for ~7 years

- **Trial Data Mining Underway**

Top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of troriluzole in SCA were announced in May 2022

- **Compelling Treatment Effect Observed**

in SCA Type 3 patients (*most common genotype*)

- **Regulatory Engagement Planned**

Engagement planned with various regulatory authorities, including Europe, before end of this year



PROUD SPONSORS OF THE ATAXIA COMMUNITY WORLDWIDE

